

THE LANCET

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Yen H-L, Sit THC, Brackman CJ, et al. Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study. *Lancet* 2022; **399**: 1070–78.

Supplementary materials

Contents:

Supplementary methods	p 2
Supplementary figure	p 4
Table S1	p 5
Table S2	p 6
Table S3	p 7
Table S4	p 8
Table S5	p 9 -15

Supplementary methods

Sample collection

All staff wore N95 masks or powered air purifying respirators, disposable coveralls, gloves and shoe covers for protection. At the time of this study investigation, animals were kept in open cages and each animal species was kept separately. For initial screening, oral and fecal swabs were randomly collected from different animal species housed in different cages in the involved pet shop and the supplying warehouse. After hamsters were identified to be infected, follow-up investigations targeted hamsters and obtained paired blood and oral swabs for laboratory investigation. Swabs samples were individually placed in virus transport medium and kept chilled with cool-packs until arrival in the laboratory. Virus transport medium comprised Medium 199 (Sigma M0393) as basal medium, 0.5% bovine serum albumin, antibiotics (penicillin G, streptomycin sulfate, polymyxin B sulfate, sulfamethoxazole, nystatin, gentamicin sulfate, ofloxacin). RT-PCR positive samples collected from the initial screening investigations were tested and independently confirmed by two laboratories (AFCD and School of Public Health, HKU). Blood samples taken from animals were kept at room temperature until arrival in the laboratory. Blood were centrifuged (3,000 rpm for 10 min at 4 °C) before harvesting serum which was stored at 4°C until testing.

RT-PCR test

RNA from swab supernatant (140 µl) was extracted by using QIAamp viral RNA minikit (Qiagen, Hilden, Germany) following the manufacturer's instructions. Eluted RNA (60 µl total) was then tested by quantitative RT-PCR assays specific for the ORF1b and N genes of SARS-CoV-2. Sequences for the primer-probe sets and RT-PCR conditions were described (Chu et al., Clin Chem 2020). Samples that were positive in both assays were classified as confirmed positives, whereas samples that were positive only in only one of these assays was classified as an inconclusive result.

Next generation sequencing

The virus genome was reverse transcribed with multiple gene-specific primers targeting different regions of the viral genome. The synthesized cDNA was then subjected to multiple overlapping 2-kb PCRs for full-genome amplification. PCR amplicons obtained from the same specimen were pooled and sequenced using ISeq sequencing platform (Illumina). The sequencing library was prepared by Nextera DNA flex. The sequencing reads generated were trimmed by fastp (Chen et al., Bioinformatics 2018) with adapter and quality filters and were mapped to a reference virus genome (Genbank accession: MN908947.3) by BWA-MEM2 (<https://github.com/bwa-mem2/bwa-mem2>). Potential PCR duplicates were identified and removed by samtools markdup (<https://www.htslib.org/doc/samtools-markdup.html>). The genome consensus sequence was generated by iVar with the PCR primer trimming protocol (minimum sequence depth >10 and minimum Q value of 30) (Grubaugh et al., Genome Biol 2019). Samples yielded poor sequencing data were excluded in the downstream analyses.

All the viral genomes deduced from this study are deposited to GISAID with the following accession numbers: EPI_ISL_9049729, EPI_ISL_9049727, EPI_ISL_9049738, EPI_ISL_9049728, EPI_ISL_9049739, EPI_ISL_9049736, EPI_ISL_9049726, EPI_ISL_9049737, EPI_ISL_9049734, EPI_ISL_9049735, EPI_ISL_9049732, EPI_ISL_9049733, EPI_ISL_9049730, EPI_ISL_9049731, EPI_ISL_9049740, EPI_ISL_9509901, EPI_ISL_9509898, EPI_ISL_9509899, EPI_ISL_9509896, EPI_ISL_9509897, EPI_ISL_9509894, EPI_ISL_9509895, EPI_ISL_9509902, EPI_ISL_9509903, EPI_ISL_9509892, EPI_ISL_9509893.

Phylogenetic analysis

Viral genomes deduced from this study were analyzed together with a set of representative sequences available in GISAID, including (1) the top 40 most similar AY.127 sequences (number of nucleotide divergence ranged from 4 to 9, compared to the local human index case sequence);

(2) the top 5 most similar AY.127 sequences from Netherlands (number of nucleotide divergence ranged from 12 to 13, compared to the local index human case sequence); (3) all previous Hong Kong AY.127 sequences; and (4) outgroup reference sequences (from Pango lineages B, B.1.1.7, B.1.351, P.1, B.1.617.1); The public sequences of AY.127 lineage were retrieved from GISAID database on 19- January-2022. The outgroup reference sequences were retrieved from a pre-subsampled pre-aligned open database from Nextstrain (https://docs.nextstrain.org/projects/ncov/en/latest/reference/remote_inputs.html).

Surrogate virus neutralization test (svNT)

svNT kits were purchased from a commercial source (GenScript, Inc., NJ, USA) and the tests were carried out according to the manufacturer's instructions. One hundred μ l of 10x diluted serum or controls samples were mixed with an equal volume of horseradish peroxidase (HRP, 6ng) conjugated to wild-type SARS-CoV-2 spike receptor binding domain (RBD) and incubated for 30 min at 37°C. Half of each mixture (100 μ l) was added to each well on the microtiter plate coated with ACE-2 receptor. The plate was sealed and incubated at room temperature for 15 min at 37°C. Plates were then washed with Wash Buffer and tapped dry. One hundred μ l of 3,3',5,5'-tetramethylbenzidine (TMB) solution was added to each well and incubated in the dark at room temperature for 15 min. The reaction was stopped by addition of 50 μ l of Stop Solution to each well and the absorbance read at 450 nm in an ELISA microplate reader. The assay validity was based on the optical density at 450 nm (OD450) for positive and negative control results falling within the recommended range.

Percent inhibition of each serum sample was calculated as follows: percent inhibition = $(1 - \text{sample OD value} / \text{negative-control OD value}) \times 100$. Percent inhibition values of $\geq 30\%$ are regarded as positive results, while percent inhibition values of $< 30\%$ are regarded as negative results.

Plaque reduction neutralization tests (PRNT)


Duplicate serial two-fold dilutions from 1:10 to 1:320 of each hamster serum sample were incubated with 30–40 plaque-forming units of SARS-CoV-2 (Delta variant) (hCoV-19/Hong Kong/21TM280310_HKUVOC0013/2021), incubated for 1 hour and added to Vero E6 over-expressing TMRESS2 cells (Matsuyama et al., PNAS 2020) grown in 24-well tissue culture plates (TPP Techno Plastic Products AG, Trasadingen, Switzerland) in a biosafety level 3 facility. After incubation for 1 h at 37° C in 5% CO₂ incubator the cell monolayer was overlaid with 1% agarose in cell culture medium and incubated for 3 days, at which time the plates were fixed and stained. The highest serum dilution that resulted in $> 50\%$ reduction in the number of virus plaques was defined as the 50% plaque reduction neutralization test (PRNT₅₀) antibody titre.

Virus isolation

Swabs with high viral load were inoculated onto Vero E6 cells overexpressing TMPRSS2 (Matsuyama et al., PNAS 2020) maintained in Dulbecco's Modified Eagle Medium (DMEM) medium (ThermoFisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) (ThermoFisher Scientific, Waltham, MA, USA) and 100 U/ml of penicillin–streptomycin (ThermoFisher Scientific, Waltham, MA, USA). The cells were observed daily for cytopathic effect and suspected virus isolates confirmed by RT-PCR as previously described (Chu et al., Clin Chem 2020).

References:

- Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics* 2018; 34(17): i884-i90.
- Chu DKW, Pan Y, Cheng SMS, et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. *Clin Chem* 2020; 66(4): 549-55.
- Grubaugh ND, Gangavarapu K, Quick J, et al. An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar. *Genome Biol* 2019; 20(1): 8.
- Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A*. 2020; 117(13):7001-7003.



Supplementary Figure. Phylogenetic Dating of most recent common ancestor of AY.127 viruses detected in hamster and human cases in this outbreak. The estimated date (95% interval range) is highlighted by an arrow. 4

Table S1. Samples collected from Syrian hamsters at Pet Shop A and the Warehouse.

Sampling location	Cage ID	Animals in cage	Animals sampled	Positive by sVNT	Confirmed PCR positive ^a	Inconclusive PCR positive ^b	Positive by sVNT or PCR ^a	Positive rate by cage
Pet Shop A	B	20	10	2	5	1	5	50%
	C	11	5	3	2	1	3	60%
	M	1	1	0	0	0	0	0%
Warehouse	C-47	1	1	1	0	1	1	100%
	C-31	1	1	1	1	0	1	100%
	C-unknown	1	1	0	0	0	0	0%
	C-48	1	1	1	0	0	1	100%
	A-75	~ 20 ^c	4	0	0	0	0	0%
	A-1	~ 4-6 ^c	2	2	0	1	2	100%
	A-2	~ 4-6 ^c	2	2	1	0	2	100%

^a Quantitative RT-PCR positive for SARS-CoV-2 N and Orf1a gene.

^b Quantitative RT-PCR positive for SARS-CoV-2 N gene alone

^c Approximate number.

Table S2. RT-PCR detection of SARS-CoV-2 infected hamsters in pet shops

Location	Animal	N	Confirmed case (+ve rate, %)^a	Inconclusive case (+ve rate, %)^b
Pet shop B	Chinchilla	6	0 (0.0%)	0 (0.0%)
	Guinea pig	2	0 (0.0%)	0 (0.0%)
	Hamster	34	0 (0.0%)	1 (2.9%)
	Rabbit	15	0 (0.0%)	0 (0.0%)
Pet Shop C	Guinea pig	8	0 (0.0%)	0 (0.0%)
	Hamster	49	2 (4.1%)	0 (0.0%)
	Rabbit	25	0 (0.0%)	0 (0.0%)
Pet Shop D	Chinchilla	16	0 (0.0%)	0 (0.0%)
	Hamster	14	0 (0.0%)	0 (0.0%)
Pet Shop E	Hamster	15	0 (0.0%)	0 (0.0%)
	Rabbit	14	0 (0.0%)	0 (0.0%)
Pet Shop F	Chinchilla	9	0 (0.0%)	0 (0.0%)
	Guinea pig	7	0 (0.0%)	0 (0.0%)
	Hamster	15	0 (0.0%)	0 (0.0%)

^aQuantitative RT-PCR positive for SARS-CoV-2 N and Orf1a gene.

^bQuantitative RT-PCR positive for SARS-CoV-2 N gene alone

Table S3: Number of nucleotide differences between viral genomes studied in this outbreak.

Sample	Number of nucleotide differences (Locations in the genome)*	
	Reference Sequence: Patient_1	Reference sequence: Patient_2
Patient_1 (Pet shop keeper)	-	5 (9430 9886 21707 24370 29670)
Patient_2 (Mother)	5 (9430 9886 21707 24370 29670)	-
Patient_3 (Father)	5 (9430 9886 21707 24370 29670)	0
Patient_5 (Son)	9 (9430 9886 21707 24370 26422 26830 27382 28277 29670)	4 (26422 26830 27382 28277)
Patient_6	6 (9430 9886 21707 22339 24370 29670)	1 (22339)
Patient_7	17(6968 6997 7002 7119 7162 7200 7262 9430 9615 12073 14772 20115 21691 21707 29635 29659 29670)	16(6968 6997 7002 7119 7162 7200 7262 9615 9886 12073 14772 20115 21691 24370 29635 29659)
Patient_8	17(6968 6997 7002 7119 7162 7200 7262 9430 9615 12073 14772 20115 21691 21707 29635 29659 29670)	16(6968 6997 7002 7119 7162 7200 7262 9615 9886 12073 14772 20115 21691 24370 29635 29659)
Patient_9	11(259 7081 7113 7194 9430 9886 12003 17510 19011 21157 21707)	10 (259 7081 7113 7194 12003 17510 19011 21157 24370 29670)
Patient_10	10(7081 7113 7194 9430 9886 12003 19011 21157 21707 28254)	10 (12 7081 7113 7194 12003 19011 21157 24370 28254 29670)
Patient_11	6 (9430 9886 21707 22339 24370 29670)	1 (22339)
Patient_12	7 (9430 9886 19329 21707 22339 24370 29670)	2 (19329 22339)
Patient_13	8 (9430 9886 20351 22339 22821 23276 24370 29670)	4 (20351 22339 22821 23276)
Patient_14	9 (9430 9886 21707 22339 24370 28254 28269 28270 29670)	4 (22339 28254 28269 28270)
Patient_15	9 (5239 9430 9886 14408 16604 21707 22339 24370 29670)	5 (2882 5239 14408 16604 22339)
HK hamster sample_1 pet_shop	1 (27549)	6 (9430 9886 21707 24370 27549 29670)
HK hamster sample_2 pet_shop	4 (5467 21707 21839 29670)	5 (5467 9430 9886 21839 24370)
HK hamster sample_3 pet_shop	1 (27549)	5 (9430 9886 24370 27549 29670)
HK hamster sample_4 pet_shop	5 (21427 21629 21663 25999 27549)	10 (9430 9886 21427 21629 21663 21707 24370 25999 27549 29670)
HK hamster sample_5 pet_shop	5 (5467 21707 21839 29696 29742)	8 (5467 9430 9886 21839 24370 29670 29696 29742)
HK hamster sample_6 pet_shop	3 (5467 21707 29670)	4 (5467 9430 9886 24370)
HK hamster sample_7 pet_shop	2 (21707 29670)	3 (9430 9886 24370)
HK hamster sample_8 pet_shop	9 (5467 6810 8204 21707 21819 21839 22063 25937 29670)	10 (5467 6810 8204 9430 9886 21819 21839 22063 24370 25937)
HK hamster sample_9 pet_shop	5 (5467 21707 21839 29670 29679)	7 (5467 9430 9886 21839 24370 29679 29808)
HK hamster sample_10 pet_shop	1 (27549)	6 (9430 9886 21707 24370 27549 29670)
HK hamster sample_11 pet_shop	1 (27549)	6 (9430 9886 21707 24370 27549 29670)
HK hamster sample_1 warehouse	13(7851 9430 9886 17358 18151 19245 21459 21549 21707 27131 29642 29670 29679)	10 (7851 17358 18151 19245 21459 21549 24370 27131 29642 29679)

*Viral genome of Patient 1 or 2 is used as the reference sequence. Sequencing gaps are ignored in this analysis.

Table S4. Non-silent mutations found in AY.127 from infected humans and hamsters.

Position	Nt mutation	Gene	AA mutation*	Patient_1 (Pet shop keeper)	Patient_2 (Mother)	Patient_3 (Father)	Patient_5 (Son)	Patient_6	Patient_7	Patient_8	Patient_9	Patient_10	Patient_11	Patient_12	Patient_13	Patient_14	Patient_15	Patient_16	Patient_17	Patient_18	Patient_19	Patient_20	Hamster_sample_1_pet_shop	Hamster_sample_1_warehouse	Hamster sample 2 pet shop	Hamster_sample_3_pet_shop	Hamster_sample_4_pet_shop	Hamster_sample_5_pet_shop	Hamster_sample_6_pet_shop	Hamster_sample_7_pet_shop	Hamster sample 8 pet shop	Hamster_sample_9_pet_shop	Hamster_sample_10_pet_shop	Hamster_sample_11_pet_shop		
21614	C/T	S	L18F	N	N	N	N	Y	Y	Y	Y	Y	Y	Y	-	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	
21707	C/T	S	H49Y	N	N	N	N	Y	N	N	N	N	N	N	-	N	N	N	N	N	N	N	Y	N	N	-	Y	N	N	N	N	N	N	Y	Y	
22842	A/G	S	D427G	N	N	N	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
29670	C/T	ORF10	T38I	N	N	N	N	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	N	N	N	N	N	Y	Y	N	N	N	Y	Y	Y	Y	Y	N	N	

* Unique amino acid mutations reproducibility found in both studied human and hamster cases;

**Studied European AY.127 sequences:

- 1) hCoV-19/Czech Republic/FNHK-Ps-002079/2021|2021-12-23|2022-01-06
- 2) hCoV-19/Czech Republic/UMTM367538/2021|2021-12-09|2022-01-13
- 3) hCoV-19/Czech Republic/NRL_16717/2021|2021-11-11|2022-01-14
- 4) hCoV-19/Czech Republic/FNHK-Ps-001677/2021|2021-12-08|2021-12-30

- Sequence gap

Table S5: SARS-CoV-2 sequences downloaded from GISAID (<https://www.gisaid.org/>) for the current study.

Accession ID	Originating lab	Submitting lab	Authors
EPI_ISL_29313 58	Home Quarantine Taskforce	Hong Kong Department of Health	Alan K.L. Tsang, Peter C.W. Yip, Ken H.L. Ng, Edman T.K. Lam, Rickjason C.W. Chan
EPI_ISL_29882 36	Platform BIS UZA/UAntwerpen	Labo Klinische Biologie, UZA	Marie Le Mercier, Jasmine Coppens, Kathleen Holemans, Ines Verbesselt, Basil Britto Xavier, Christine Lammens, Veerle Matheeußen, Herman Goossens
EPI_ISL_33856 38	Arizona State University	Arizona State University	Ajeet Bains, LaRinda A. Holland, Matthew F. Smith, Peter T. Skidmore, Rabia Maqsood, Nicholas J. Mellor, Nathaniel Johnson, Joshua LaBaer, Vel Murugan, Efrem S. Lim
EPI_ISL_33901 90	Dutch COVID-19 response team	National Institute for Public Health and the Environment (RIVM)	Adam Meijer, Harry Vennema, Dirk Eggink, Jeroen Cremer, Sharon van den Brink, Bas van der Veer, AnneMarie van den Brandt, Lisa Wijsman, Kim Freriks, Ryanne Jaarsma, Eunice Then, Lynn Aarts, Sanne Bos, Stijn van Rossum, Florian Zwagemaker, Dennis Schmitz, Annelies Kroneman, Karim Hajji, Chantal Reusken, on behalf of the national COVID-19 response team
EPI_ISL_34532 16	National Platform bis UMONS/Jolimont	National Platform bis UMONS/Jolimont	François Dufrasne, Guillaume Bayon-Vicente, Florian Juszcak, Laetitia Gheysen, Eric Tarantino, Gautier Detry, Ruddy Wattiez
EPI_ISL_38684 82	Lab voor klinische biologie	Lab voor klinische biologie	Marija Janevska, Hannelore Hamerlinck, Bruno Verhasselt
EPI_ISL_43426 61	North Lantau Hospital	Hong Kong Department of Health	Alan K.L. Tsang, Peter C.W. Yip, Ken H.L. Ng, Edman T.K. Lam, Rickjason C.W. Chan
EPI_ISL_43426 66	Home Quarantine Taskforce	Hong Kong Department of Health	Alan K.L. Tsang, Peter C.W. Yip, Ken H.L. Ng,

			Edman T.K. Lam, Rickjason C.W. Chan
EPI_ISL_45422 52	WSSE w Olsztynie	Wojewodzka Stacja Sanitarno-Epidemiologiczna w Olsztynie, Laboratorium Badan Epidemiologiczno-Klinicznych	Sylvia Krzetowska, Monika Czerminska, Ewa Liszewska, Tomasz Jakubczak, Marta Lukian, Patryk Bielecki, Aleksandra Kobiatko, Emilia Tarabasz, Paulina Rozycka, Barbara Dolinska
EPI_ISL_54033 55	KU Leuven, Rega Institute, Clinical and Epidemiological Virology	KU Leuven, Rega Institute, Clinical and Epidemiological Virology	Tony Wawina-Bokalanga, Bert Vanmechelen, Joan Marti-Carerras, Piet Maes
EPI_ISL_58046 58	Jordan Royal Medical Services Mobile Biological Lab	Jordan Royal Medical Services Genomics Core Lab	Dr. Rame Hamdi khasawneh, Ali Alhuniti, Osama Alshdaifat, Mohammad Barmawi , Abdullah Almuhasen , Alanood Alhabashnah Suzan D. Pas, Jaco J. Verweij, Joep J. J. M. Stohr
EPI_ISL_58528 75	Microvida	Microvida	
EPI_ISL_60185 39	Northumbria University / South Tees Hospitals NHS Foundation Trust / North Cumbria Integrated Care NHS Foundation Trust / North Tees and Hartlepool NHS Foundation Trust / Newcastle Hospitals NHS Foundation Trust	COVID-19 Genomics UK (COG-UK) Consortium	Darren L Smith, Andrew Nelson, Matthew Bashton, Greg R Young, Joshua Loh, John Allan, Mohammad A Tariq, Giles S Holt, Gary Black, Wen C Yew, Lynn Dover, Paul Baker, Steve Liggett, Sarah Essex, Jane Greenaway, Debra Padgett, Clive Graham, Garren Scott, Edward Barton, Emma Swindells, Brendan Payne, Jennifer Collins, Yusri Taha, Gary Eltringham
EPI_ISL_60475 50	Lighthouse Lab in Glasgow	Wellcome Sanger Institute for the COVID-19 Genomics UK (COG-UK) Consortium	Harper VanSteenhouse, Yumi Kasai, David Gray, Carol Clugston, Anna Dominiczak and Alex Alderton, Roberto Amato, Jeffrey Barrett, Sonia Goncalves, Ewan Harrison, David K. Jackson, Ian Johnston, Dominic Kwiatkowski, Cordelia Langford, John Sillitoe on behalf of the Wellcome Sanger Institute

COVID-19 Surveillance
Team

EPI_ISL_62993 07	Lighthouse Lab in Milton Keynes	Wellcome Sanger Institute for the COVID- 19 Genomics UK (COG- UK) Consortium	The Lighthouse Lab in Milton Keynes and Alex Alderton, Roberto Amato, Jeffrey Barrett, Sonia Goncalves, Ewan Harrison, David K. Jackson, Ian Johnston, Dominic Kwiatkowski, Cordelia Langford, John Sillitoe on behalf of the Wellcome Sanger Institute COVID-19 Surveillance Team
EPI_ISL_66020 81	Viesoji istaiga Vilniaus universiteto ligonine Santaros klinikos	Vilnius University Hospital Santaros Klinikos, Center of Laboratory Medicine	Daniel Naumovas, Ligita Raugaite, Monika Katenaite, Rimvydas Norvilas, Dovile Juozapaite, Ingrida Olendraite, Gytis Dudas Martinetti Lucchini Gladys, Valeria Spina
EPI_ISL_66859 28	Labor team w AG	Laboratorio di Microbiologia, Istituto di Medicina di Laboratorio EOLAB, Ente Ospedaliero Cantonale	
EPI_ISL_68538 78	Dutch COVID-19 response team	National Institute for Public Health and the Environment (RIVM)	Adam Meijer, Harry Vennema, Dirk Eggink, Jeroen Cremer, Sharon van den Brink, Bas van der Veer, AnneMarie van den Brandt, Lisa Wijsman, Kim Freriks, Ryanne Jaarsma, Lynn Aarts, Sanne Bos, Stijn van Rossum, Linda van Someren, Florian Zwagemaker, Dennis Schmitz, Annelies Kroneman, Karim Hajji, Ivo van Walle, Chantal Reusken, on behalf of the national COVID-19 response team
EPI_ISL_69479 67	CDPH VBL	California Department of Public Health	Emily Smith on behalf of CDPH-COVIDNet
EPI_ISL_69539 36	Labor Blackholm MVZ	Robert Koch Institute	unknown

EPI_ISL_71114 66	Labor Dr. Wisplinghoff - Köln	Robert Koch Institute	unknown
EPI_ISL_71610 14	Virology Department, Royal Infirmary of Edinburgh, NHS Lothian / School of Biological Sciences, University of Edinburgh	COVID-19 Genomics UK (COG-UK) Consortium	McHugh M, Dewar R, Cotton S, Gallagher A, Maloney D, Fernandez G, O'Toole Á, Scher E, Hill V, McCrone JT, Colquhoun R, Yu X, Jackson B, Rambaut A, Templeton K Dusan Loderer, Katarina Janikova, Ivana Kasubova, Maria Skerenova, Marian Grendar
EPI_ISL_72118 29	Public Health Authority of the Slovak Republic	Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University	PHE Covid Sequencing Team
EPI_ISL_73469 67	Respiratory Virus Unit, Microbiology Services Colindale, Public Health England	COVID-19 Genomics UK (COG-UK) Consortium	
EPI_ISL_73729 61	Synlab	Laboratorio di Microbiologia	Martinetti Lucchini Gladys, Valeria Spina
EPI_ISL_73805 87	Public Health Authority of the Slovak Republic	Public Health Authority of the Slovak Republic	Barbora Kotvasová, Lucia Ševčíková, Terézia Vrabľová, Anna Gičová, Elena Tichá, Miroslav Böhmer, Tomáš Szemes, Pavol Mišenko
EPI_ISL_74065 23	Quarantine Camp	Hong Kong Department of Health	Alan K.L. Tsang, Peter C.W. Yip, Patricia K. L. Leung, Ken H.L. Ng, Edman T.K. Lam, Rickjason C.W. Chan
EPI_ISL_74066 07	North Lantau Hospital	Hong Kong Department of Health	Alan K.L. Tsang, Peter C.W. Yip, Patricia K. L. Leung, Ken H.L. Ng, Edman T.K. Lam, Rickjason C.W. Chan
EPI_ISL_74209 56	Labor Dr. Wisplinghoff - Köln	Robert Koch Institute	unknown
EPI_ISL_74369 63	Labor Dr. Wisplinghoff - Köln	Robert Koch Institute	unknown
EPI_ISL_75446 09	Broad Institute Clinical Research Sequencing Platform	Infectious Disease Program, Broad Institute of Harvard and MIT	Siddle,K.J., Adams,G., Pearlman,L., Gladden- Young,A., Vicente,G., Blumenstiel,B., DeFelice,M., Lee,M., McGovern,S., Lagerborg,K., Rudy,M., DeRuff,K., Carter,A., Normandin,E., Bauer,M., Reilly,S., Tomkins- Tinch,C., Loreth,C., Chaluvadi,S., Meldrim,J., Granger,B., Lemieux,J.E., Birren,B.W., Sabeti,P.C., Larkin,K., Dodge,S.,

Lennon,N., Madoff,L.,
Brown,C., Gallagher,G.,
Smole,S., Park,D.J.,
Gabriel,S., and
MacInnis,B.L.

EPI_ISL_76998 56	NYU Langone Health	Departments of Pathology and Medicine, New York University School of Medicine	Adriana Heguy, Dacia Dimartino, Emily Guzman, Christian Marier, Peter Meyn, Sitharam Ramaswami, Gael Westby, Paul Zappile, Yutong Zhang, Guiqing Wang
EPI_ISL_77048 32	Laboratoire de santé publique du Québec	Laboratoire de santé publique du Québec	Sandrine Moreira, Ioannis Ragoussis, Guillaume Bourque, Jesse Shapiro, Mark Lathrop and Judith Fafard on behalf of the CoVSeQ research group
EPI_ISL_77051 24	Laboratoire de santé publique du Québec	Laboratoire de santé publique du Québec	Sandrine Moreira, Ioannis Ragoussis, Guillaume Bourque, Jesse Shapiro, Mark Lathrop and Judith Fafard on behalf of the CoVSeQ research group
EPI_ISL_77051 42	Laboratoire de santé publique du Québec	Laboratoire de santé publique du Québec	Sandrine Moreira, Ioannis Ragoussis, Guillaume Bourque, Jesse Shapiro, Mark Lathrop and Judith Fafard on behalf of the CoVSeQ research group
EPI_ISL_77141 00	Laboratoire de santé publique du Québec	Laboratoire de santé publique du Québec	Sandrine Moreira, Ioannis Ragoussis, Guillaume Bourque, Jesse Shapiro, Mark Lathrop and Judith Fafard on behalf of the CoVSeQ research group
EPI_ISL_77279 94	Fakultní nemocnice Bulovka	Institute of Molecular Genetics CAS	Jan Pačes, Miluše Hradilová, Jana Šáchová, Martin Zmuda, Ondřej Moravčík, Lucie Pfeiferová, Michal Kolář

EPI_ISL_79245 79	Laboratoria Medyczne Bruss grupa ALAB sp. z o.o.; Medyczne Laboratorium Diagnostyczne, Pracownia Genetyki	1. Tricity SARS-CoV-2 sequencing consortium: University of Gdansk, Medical University of Gdansk, Vaxican Ltd., Invicta Ltd. 2. National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland	Maciej Kosinski, Celina Cybulska, Krystyna Bienkowska Szewczyk, Maciej Grzybek, Karolina Gackowska, Marcin Lubocki, Katarzyna Groth, Lukasz Rabalski, Katarzyna Zacharczuk, Magdalena Nowakowska, Małgorzata Sadkowska- Todys, Tomasz Wolkowicz
EPI_ISL_80619 88	Nemocnice Hodonin	University Hospital Brno, CMBG	Bezdicek Matej, Svaton Jan, Kristyna Dufkova, Lengerova Martina, Dolejska Monika
EPI_ISL_81318 40	UW Virology Lab	UW Virology Lab	Pavitra Roychoudhury, Shah Mohamed Bakhsh, Seffir T. Wendm, Isabel Arnould, Pooneh Hajian, Hong Xie, Sean Ellis, Nathan Breit, Robert J. Livingston, Meei-Li Huang, Keith R Jerome, Patrick Mathias, Alexander Greninger Stefan Boers
EPI_ISL_82036 38 EPI_ISL_82075 06	Haaglanden Medisch Centrum Pardubicka nemocnice	Leiden University Medical Center University Hospital Hradec Kralove	Marketa Gancarcikova, Helena Kovarikova, Lenka Rysava, Monika Berankova
EPI_ISL_82171 97	MVZ Labor Dr. Quade & Kollegen GmbH	Robert Koch Institute	unknown
EPI_ISL_82172 00	MVZ Labor Dr. Quade & Kollegen GmbH	Robert Koch Institute	unknown
EPI_ISL_82220 77	Labor Dr. Wisplinghoff - Köln	Robert Koch Institute	unknown
EPI_ISL_82250 31	Eurofins MVZ Labor Gelsenkirchen	Robert Koch Institute	unknown
EPI_ISL_84083 93	University Hospital Hradec Kralove	University Hospital Hradec Kralove	Marketa Gancarcikova, Helena Kovarikova, Lenka Rysava, Monika Berankova
EPI_ISL_84231 01	Dutch COVID-19 response team	Erasmus Medical Center	Bas Oude Munnink, Reina Sikkema, David Nieuwenhuijse, Irina Chestakova, Anne van der Linden, Marjan Boter, Emmanuelle Munger, Corine GeurtsvanKessel, Annemiek van der Eijk, Richard Molenkamp, Marion Koopmans, on

behalf of the Dutch national COVID-19 response team.

EPI_ISL_86574 96	CGB laboratoř, a.s.	Institute of Molecular and Translational Medicine / Laboratory of Experimental Medicine, Faculty of Medicine and Dentistry, Palacky University	Rastislav Slavkovský, Hana Jaworek, Vladimíra Koudeláková, Barbora Blumová, Kateřina Kubáňová, Marián Hajdúch
EPI_ISL_87251 90	National Institute of Public Health	National Institute of Public Health	Helena Jirincova, Jaromira Vecerova, Timotej Suri, Alexander Nagy
EPI_ISL_88800 79	North Lantau Hospital	Hong Kong Department of Health	Alan K.L. Tsang, Peter C.W. Yip, Patricia K. L. Leung, Ken H.L. Ng, Edman T.K. Lam, Rickjason C.W. Chan
EPI_ISL_88800 80	St. Paul's Hospital	Hong Kong Department of Health	Alan K.L. Tsang, Peter C.W. Yip, Patricia K. L. Leung, Ken H.L. Ng, Edman T.K. Lam, Rickjason C.W. Chan
EPI_ISL_88800 83	Queen Mary Hospital	Hong Kong Department of Health	Alan K.L. Tsang, Peter C.W. Yip, Patricia K. L. Leung, Ken H.L. Ng, Edman T.K. Lam, Rickjason C.W. Chan

We gratefully acknowledge the following Authors from the Originating laboratories responsible for obtaining the specimens and the Submitting laboratories where genetic sequence data were generated and shared via the GISAID Initiative, on which this research is based.